Answers are grounded in this paper and cite their sources.
Morbidity and mortality of HIV-infected patients have been improved over the last decades with the advent of combined antiretroviral therapy.As a result, other comorbidities such as chronic kidney and chronic liver diseases have emerged in the HIV population.A considerable percentage of end-stage liver disease (ESLD) in HIV population is attributed to hepatitis C co-infection and reactivation, and a growing need for solid organ transplantation has emerged among those patients.On the other hand, several studies on liver transplantations of patients co-infected with human immunodefi ciency virus (HIV) and hepatitis C virus (HCV) have shown discouraging results both in patient and graft survival rates.As a result, HIV-HCV co-infection has been considered a relative contraindication for liver transplantation.Thankfully, new drugs for HCV treatment have been discovered, acting direct on viral replication of HCV and they have changed the whole clinical course of HCV/HIV co-infected liver transplant recipients.Our case illustrates the long-term effi cacy and safety of the new combination of Sofosbuvir/Ledipasvir in HCV/HIV co-infected liver transplant recipients.
No takes yet. Share an insight, caveat, or question.
Zorbas KA (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: